What happens to your testosterone prescription in 2027

If you get testosterone through a telehealth visit, there's a date on the federal calendar you should know about: December 31, 2026. After that, the rule that lets your prescriber write that prescription without ever examining you in person expires.

Your estradiol patch isn't affected. Your progesterone isn't affected. Just the testosterone.

I use testosterone myself, prescribed through telehealth, so I've been reading the actual regulations instead of the panic posts. Here's what's really going on, what could happen in 2027, and what's worth doing about it now. I'm a medical technologist, not a doctor, so treat this as a well-sourced explainer to bring to your own clinician, not medical advice.

Why testosterone is different from your other hormones

Estradiol and progesterone are ordinary prescription drugs. Any licensed prescriber can send them to your pharmacy from a video visit, no special federal rules involved.

Testosterone got swept into the Controlled Substances Act as a Schedule III drug in 1990, when Congress was worried about anabolic steroid abuse in sports. Your 5 milligrams of daily cream is regulated under the same framework as a bodybuilder's black-market vials. That was a political decision, not a medical one, and women have been living with the consequences for 35 years.

Schedule III status means three practical things for you:

• Your prescriber needs a DEA registration, not just a medical license
• Refills are capped at 5 within 6 months, then you need a new prescription
• Telehealth prescribing runs under special federal rules, and those are the rules that expire

There's another wrinkle worth knowing. No FDA-approved testosterone product for women exists in the United States. Every prescription is off-label, either a fraction of a male-dosed product or a compounded cream. It's still legitimate and guideline-supported: the 2019 Global Consensus Position Statement, endorsed by the Endocrine Society and The Menopause Society among others, backs testosterone for hypoactive sexual desire disorder in postmenopausal women. But off-label plus Schedule III is why getting it has always involved more friction than your estrogen. If you want the deeper version of that story, I wrote about the whole testosterone picture for women in this piece.

The rule that expires December 31, 2026

Back in 2008, Congress passed the Ryan Haight Act. It requires at least one in-person medical evaluation before a prescriber can give you any controlled substance through telemedicine. One exam, once, then telehealth is fine.

When COVID hit in March 2020, the DEA waived that requirement so care could continue. Telehealth medicine exploded, including menopause platforms like Midi and Alloy, and the waiver turned out to work. So instead of writing permanent rules, the DEA has extended it. Four times now.

The current one, the Fourth Temporary Extension, runs January 1 through December 31, 2026. Under it, a DEA-registered prescriber can legally prescribe testosterone to a patient she's never met in person, as long as it's for a legitimate medical purpose and follows state law.

That's the whole cliff: the temporary permission expires at the end of this year, and the permanent replacement isn't public yet. I checked the Federal Register and DEA announcements this month (July 2026). No fifth extension has been announced, and no permanent rule has been published. But there's one signal worth watching, and I'll get to it in Scenario 2, because it changes the odds.

The three ways 2027 can go

Scenario 1: A fifth extension. The DEA has kicked this can four times, and each extension has arrived in the final weeks of the year, often the last day. A fifth extension is entirely plausible, and it's the path of least resistance for an agency that hasn't finished its permanent rule. If this happens, nothing changes for you, your prescription continues exactly as it does now, and we do this same dance again heading into 2028. Boring is good here. Boring means your access didn't move.

Scenario 2: The permanent rule gets finalized. In January 2025 the DEA proposed a Special Registration for Telemedicine: a permanent system where telehealth prescribers and platforms register with the DEA to prescribe Schedule III through V drugs remotely. For eighteen months it sat unfinished. Then, in November 2025, the DEA sent a final telemedicine-prescribing rule to the White House budget office (OMB) for review. That matters, because OMB review is the last stop before a rule becomes official. It's the strongest sign yet that a permanent framework, not just another temporary patch, could actually land. If it does, your telehealth prescription most likely continues, but your provider takes on new registration paperwork, and some smaller practices may decide the compliance burden isn't worth it. Watch the platform you use, not just the headline.

Scenario 3: Nothing happens and the old rule snaps back. If the extension lapses with no replacement, the Ryan Haight in-person requirement returns. That doesn't ban telehealth testosterone. It means you'd need one in-person medical evaluation before, or in some arrangements connected to, your telehealth prescribing relationship. That's genuinely annoying if your prescriber is three states away and you chose telehealth precisely because there's no menopause-literate doctor near you. It is not the end of your treatment, and it's the least likely of the three now that a final rule is sitting at OMB.

Notice what's not on this list: any scenario where testosterone for women becomes illegal, or your current bottle gets confiscated, or you're forced off treatment. The worst realistic case is an extra appointment.

What to do now

1. Ask your telehealth provider one question: "What's your plan if the DEA flexibilities expire December 31?" The big platforms have compliance teams working on exactly this. A good answer sounds like "we're building in-person exam options through partner clinics" or "we'll email every patient before anything changes." A vague answer, or a shrug, is useful information too. It tells you whether to line up a backup.
2. Know that one in-person visit may cover you. The baseline Ryan Haight requirement is a single in-person medical evaluation, not a permanent move back to in-office care. If Scenario 3 arrives, one appointment, potentially with a local clinician your telehealth provider partners with, may be what bridges you. Ask whether an in-person exam you've already had on record counts.
3. Keep your own records. Save your current prescription details, your dose, and your recent testosterone labs somewhere you can find them. If you do end up needing a new prescriber or an in-person visit, walking in with your history makes the handoff faster and keeps you from starting over.
4. Don't stockpile. Federal law caps testosterone at 5 refills in 6 months anyway, and hoarding a controlled substance is a genuinely bad idea, legally and medically. There will be a transition path. There always has been, through four extensions.
5. Relax about the rest of your HRT. Estradiol, progesterone, vaginal estrogen: not controlled substances, not part of this, completely unaffected no matter what happens in December.
6. Watch for news in Q4. The last extensions were announced in November and December. If you hear nothing by Thanksgiving, that's normal, not ominous. And if you specifically want to know whether the permanent rule cleared OMB, that's the single development most worth tracking this fall.

A note on pellets, since this is where a lot of the friction lives

If you're on pellets, the same telehealth rules apply, but pellets add their own wrinkle: they're inserted in person, they can't be dose-adjusted once they're in, and they often push testosterone well above the female range. That's a separate conversation from the DEA calendar, and I've written about the specific tradeoffs, including the endometrial question, here. Worth reading before your next insertion, whatever happens in Washington.

The part that actually annoys me

Women fought for years to get clinicians to take low libido seriously, got a consensus statement from every major menopause society, and still can't get an FDA-approved product. Now the access route that finally made treatment reachable, for women in rural areas, or women whose local doctors won't prescribe it, hangs on a temporary rule that gets renewed a few weeks before it expires, year after year.

The 2027 testosterone question was never really about safety. It's a scheduling decision from 1990, aimed at bodybuilders, still deciding whether a 57-year-old woman needs to drive to an office.

The calm version of the truth is this: nobody is coming for your treatment, the machinery is slow and bureaucratic, and the most likely outcomes are "nothing changes" or "one extra appointment." Know the date. Ask your provider the question. Then go back to living.

---

Send this to someone who gets her testosterone through a screen. She should know the date, and she shouldn't panic about it.

If you want to go deeper, the Alliance for Connected Care tracker follows every DEA move on this, and the consensus statement on testosterone for women is worth reading before your next appointment. As always: I read the research and the regulations, but decisions about your prescription belong in a conversation with a qualified clinician who knows your history.

If this kind of plain-English breakdown is useful, subscribing gets you the follow-up the day the DEA finally acts.

Sources verified 2026-07-11 (regulatory status re-confirmed July 2026)

• DEA Fourth Temporary Extension, Federal Register, Dec 31 2025
• DEA press release on the extension
• HHS & DEA extend telemedicine flexibilities through 2026
• Proposed Special Registrations for Telemedicine rule, Jan 17 2025
• DEA final rule at OMB (Nov 2025) indicates a permanent rule is near
• Alliance for Connected Care DEA tracker
• Global Consensus Position Statement on Testosterone Therapy for Women, JCEM 2019
• WebSearch re-check July 2026: no fifth extension announced; Special Registration rule still not finalized; a DEA final telemedicine rule was submitted to OMB for review in November 2025.